Belgian biotherapeutics firm AgomAb inks Series A funding
AgomAb, a Belgian biotherapeutics company, has secured 21 million euros in Series A funding. V-Bio Ventures and Advent France Biotechnology led the round with participation from Boehringer Ingelheim Venture Fund, Omnes and Pontifax.
3 April 2019•1 min read
